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Abstract
Background—Chemotherapy administration and supportive management for solid tumors is 
intended to take place in the ambulatory setting, but little is known about why some patients 
experience treatment-related, adverse events so severe as to require acute inpatient care.
Objective—Identify predictors of initial and repeated unplanned hospitalizations and potential 
financial impact among Medicare patients with early-stage (stages I–III) colorectal cancer 
receiving outpatient chemotherapy.
Methods—Advanced statistical modeling was used to analyze a cohort of patients (N = 1485) 
from the Surveillance, Epidemiology and End Results (SEER)–Medicare database diagnosed from 
2003–2007 with colorectal cancer as their first primary malignancy. Patients were age 66 and 
older at diagnosis, had uninterrupted Medicare Parts A and B coverage with no health 
maintenance organization (HMO) component, and received chemotherapy at least one time.
Results—Female sex, younger age, multiple comorbidities, rural geography, higher high school 
completion rates, and lower median income per census tract were significant predictors of the 
likelihood of initial unplanned hospitalizations. Non-White race, receipt of radiation therapy, rural 
geography and higher weighted comorbidity scores were factors associated with the number of 
hospitalizations experienced. The total Medicare charges calculated for these admissions was 
$38,976,171, with the median charge per admission at $20,412.
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Discussion—Demographic and clinical factors were identified that form the foundation of work 
towards development of a risk factor profile for unplanned hospitalization. Further work is needed 
to incorporate additional clinical data to create a clinically applicable model.
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Quality and value are critical to processes and outcomes in effective and efficient health 
systems. Unplanned and potentially avoidable hospitalization events may signal lapses in 
quality and contribute to diminished value. Factors associated with unplanned and 
potentially avoidable hospitalization are not well understood.
In oncology, chemotherapy for solid tumors (such as colorectal cancers) is intended to be 
administered and managed primarily in the outpatient setting once initial surgery to resect 
disease is completed; however, a proportion of patients will experience treatment-related 
symptoms so severe as to disrupt therapy and require inpatient care to resolve. The 
therapeutic goal in early-stage (stages I–III) disease is to cure or achieve long-term disease 
remission, and therefore every attempt is made for this population to provide full doses of 
drug on the prescribed schedule. The average age at colorectal cancer diagnosis is 69 
(Howlader et al., 2015), and though older adults typically experience the highest proportion 
of cancer diagnoses annually, they tend to be underrepresented in clinical trials, limiting 
knowledge about how adverse events are precipitated and experienced by this population. 
This study uses the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End 
Results (SEER)–Medicare database to develop a cohort of older adult patients with early-
stage colorectal cancer to identify factors associated with both an initial unplanned 
hospitalization as well as repeated readmissions over the course of chemotherapy 
administration. The use of a large dataset such as SEER–Medicare allows exploration of 
“real world” data outside of the clinical trial setting, and a longitudinal view of care across 
settings ranging from prior to cancer diagnosis and throughout the treatment trajectory.
Related Literature
Unplanned Hospitalization
Factors associated with the initial unplanned hospitalization in a population intended to 
receive care exclusively in the outpatient setting may be distinct from readmission, where a 
patient is discharged from an inpatient stay, then must return to the hospital for further 
planned or unplanned inpatient care (Fessele & Atkins, 2012; Jencks, Williams, & Coleman, 
2009; Mulder, Tzeng, & Vecchioni, 2012). Unplanned hospitalization is defined as “an 
unexpected admission for management of a severe disease or treatment-related event that 
cannot be controlled in the outpatient setting” (Fessele & Atkins, 2012), and for this study, it 
was limited to those occurring during the period during which the patient is receiving 
chemotherapy. Patients with metastatic or stage IV disease were excluded from this analysis 
to minimize the inclusion of hospitalizations related to cancer progression.
As data regarding these events are limited for this population, larger scale studies are needed 
to identify factors related to the incidence of initial, unplanned hospitalization and multiple 
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readmissions in the patients intended to be treated exclusively in the outpatient setting. Any 
unplanned hospitalization may present a significant clinical disruption in regards to the 
ability to maintain potentially curative chemotherapy dose and schedule, exposure to 
possible nosocomial and iatrogenic complications, financial burdens associated with an 
inpatient stay, and the impact on the patient and family’s quality of life (Aparicio et al., 
2013; Calfee, 2012).
Colorectal cancer was selected as the focus of this study as this tumor type has been 
described among the most frequently admitted in several reviews (Grant, Ferrell, Rivera, & 
Lee, 1995; Hassett et al., 2011; Weaver et al., 2006). Reports from single institution-based 
studies in patients with colorectal cancer indicate that higher (stages III and IV) disease 
stage, receipt of chemotherapy or radiation therapy, multiple (three or more) comorbidities, 
and inadequate support in the home are associated with unplanned hospitalizations 
(González et al., 2005; Hassett et al., 2011; Weaver et al., 2006).
Prior large dataset studies exploring predictors of unplanned hospitalizations among patients 
with several cancers also found that the presence of multiple comorbidities, higher disease 
stage (Nurgalieva, Liu, & Du, 2009), unmarried status, race, and geographic location (Du, 
Osborne, & Goodwin, 2002) were significant predictors of unplanned hospitalization. In 
addition, higher rates of toxicity among older adults compared to those reported in clinical 
trials associated with the administered regimens were noted (Du et al., 2002; Hassett, 
O’Malley, Pakes, Newhouse, & Earle, 2006).
Though current geriatric oncology guidance recommends assessment of a patient’s 
physiologic rather than chronologic age to determine appropriate use of chemotherapy for 
older adults, it is acknowledged that some major organ function changes do occur with time, 
such as decreased renal and bone marrow function (Extermann et al., 2002), possibly 
impacting the incidence and severity of adverse events that might interrupt treatment. 
Underrepresentation of older adults in clinical trials limits the data available to interpret 
risks to this group (Hurria et al., 2015).
There is evidence that sex may play a role in determining the degree of toxicity experienced. 
Females receiving chemotherapy for colorectal cancers have been noted to experience 
higher rates of myelosuppression, diarrhea and mucositis in several studies (González et al., 
2005; Nottage et al., 2003; Pal & Hurria, 2010; Sloan et al., 2002; Zalcberg, Kerr, Seymour, 
& Palmer, 1998). This may be related to biologic differences in clearance of 5-fluorouracil
—the most commonly administered drug—though the exact mechanism underlying this 
observation is unclear.
Purpose
This study focuses on patients receiving chemotherapy for early-stage disease for colorectal 
cancer intended to be delivered exclusively in the outpatient setting, and the identification of 
predictors of both initial hospitalization and multiple readmissions. This work fills an 
important gap in literature, as no data were found addressing these problems in this 
population. The first aim examined which demographic and clinical factors were associated 
with an initial, unplanned hospitalization in patients with early-stage colorectal cancer in the 
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SEER-Medicare linked database. The second aim studied which factors were associated 
with the number of readmissions for treatment-related, serious adverse events in these 
patients. An exploratory aim was to identify the potential financial impact of these 
unplanned hospitalizations.
Methods
Data Source
Data for this study originate from the SEER–Medicare linked database, which combines 
information from two sources: the National Cancer Institute’s SEER program and the Center 
for Medicare and Medicaid Services (CMS) claims data through a linking process to allow 
researchers to view clinical and administrative data for a single patient across time and 
settings of care (Warren, Klabunde, Schrag, Bach, & Riley, 2002). The SEER program has 
collected data on incident cancer cases diagnosed within 17 cancer registries across the 
United States since 1973, capturing approximately 28% of all national cases (NCI, 2012). 
SEER data includes patient demographics, cancer type, stage, initial surgical and radiation 
treatments (but not specific chemotherapy regimens), and survival status, and the quality of 
data is considered highly valid according to the North American Association of Central 
Cancer Registries (Bray & Parkin, 2009).
Medicare, a federally administered health insurance program, covers approximately 93% of 
Americans over age 65 (U.S. Department of Health and Human Services, 2014), which 
automatically includes Part A benefits that provide for hospital and skilled-nursing facility 
costs, as well as hospice and some other home health services. About 96% of covered 
beneficiaries choose to obtain Part B benefits, which cover physician and outpatient 
services. Parts C and D optional benefits cover Health Maintenance Organization (HMO) 
plans for which CMS is payor, and prescription drug coverage, respectively (CMS, 2012).
The SEER–Medicare database comprised several file types, each generated from a separate 
source. Table 1 illustrates the main file types in this study, including the unit of 
measurement in each file. The Patient Entitlement and Diagnosis Summary File (PEDSF) 
originates from the SEER registry information, and is formatted as one observation per 
patient case. The availability of PEDSF data at the start of this study included cases 
diagnosed with colorectal cancer through 2007, with claims-derived data for each case 
through 2009. For example, the record of a patient diagnosed with colorectal cancer in 2005 
was found in the PEDSF file for that tumor type and year, and included all of the SEER 
registry information. A researcher then explored the patient’s associated Medicare-derived 
files from 2004 (prior to the cancer diagnosis to identify pre-existing comorbid conditions) 
through the end of available data in 2009.
The Medicare Provider Analysis and Review (MEDPAR) File is derived from the Medicare 
Part A claims data generated during a hospitalization. Each observation within MEDPAR 
represents a single hospital stay for a SEER–Medicare patient. The National Carrier History 
(NCH) and Outpatient (OUTPT) files describe services such as provider visits and 
treatments administered in the ambulatory setting. NCH data represents provider claims 
from physicians, nurse practitioners, and physician assistants empaneled as independent 
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Medicare providers across settings and specialties, as well as claims from laboratory and 
freestanding ambulatory care centers. OUTPT data represents similar claims from the 
outpatient departments within hospitals, and are separate in nature and structure from the 
MEDPAR claims.
Each observation in the NCH and OUTPT files represents a single-billed line item. Using a 
hypothetical scenario to illustrate a one-day chemotherapy administration in a private 
oncologist’s office; the researcher might note several separate observations for the same date 
in the NCH file, including the provider exam, a complete blood count to assure patient 
eligibility prior to treatment, each individual drug charge, and an administration charge 
(Lamont et al., 2005). The initial variable in the PEDSF, MEDPAR, NCH, and OUTPT files 
is the patient identification (ID) assigned by SEER-Medicare, allowing desired data to be 
obtained for a particular patient as he or she receives care and generates claims to Medicare 
at various locations over time.
Population and Cohort Construction
The Rutgers University Institutional Review Board deemed use of the SEER–Medicare 
database as nonhuman subject research, and the study was authorized to proceed. Files were 
initially obtained inclusive of the entire population of Medicare-eligible patients diagnosed 
in contributing SEER registry areas with the desired cancer type for the years requested. 
Cases were retained initially if the patient had stage I–III colorectal cancer diagnosed in the 
years 2003 through 2007, was 66 years of age or greater at the time of cancer diagnosis, and 
had continuous Parts A and B Medicare coverage during the period of observation—but no 
participation in Part C (HMO). Cases diagnosed on autopsy or by death certificate only were 
excluded (see Figure 1 for cohort construction numbers). No sampling occurred so as to 
capture the entire possible population eligible for inclusion.
Cohort construction was designed to identify all eligible patient cases with early-stage 
colorectal cancer who received chemotherapy in the ambulatory setting, including those who 
experienced a subsequent hospitalization within 30 days of treatment administration. 
Patients who received chemotherapy were identified by searching the multiyear ambulatory 
claims files (NCH and outpatient) for observations with a billing code containing a J9 value, 
which designates chemotherapy agents (Lamont et al., 2005). Cancer-related 
hospitalizations (as opposed to hospitalizations for noncancer conditions in patients with a 
history of cancer) were identified by searching the multiyear hospital claims file (MEDPAR) 
for the tumor type of interest in either the first or second position of 10 possible 
International Classification of Diseases (ICD)-9-CM diagnostic codes assigned to the 
admission (Mayer, Travers, Wyss, Leak, & Waller, 2011). When a patient case was located 
in both “received chemotherapy” and “had a cancer-related hospitalization” file searches, 
that case was assigned to the “hospitalized” group (Figure 2). When codes for chemotherapy 
administration or a surgical procedure were found in a MEDPAR file observation, the 
hospitalization was removed from final analysis to restrict the events of interest to 
unplanned hospitalizations likely to be related to treatment-related, adverse events rather 
disease progression within the cohort or staging surgeries. Where a case was found in the 
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“received chemotherapy” file only, that patient was assigned to the “no hospitalization” 
group.
Medicare Coverage
To optimize the capture of billed claims and the associated diagnostic coding information, 
SEER–Medicare researchers typically apply what is referred to as “most likely to have 
(consistent) claims” criteria (Warren et al., 2002). By ensuring uninterrupted Medicare Parts 
A and B coverage, with no transfer into a Medicare HMO product over the course of the 
study, the researcher is most able to detect all diagnostic codes and claims for a patient as 
they receive services from providers and institutions that accept this insurance. The key 
observation time periods for this study included a one-year period prior to cancer diagnosis 
to identify pre-existing comorbidities, and a hospitalization observation period, ranging from 
the day after the first chemotherapy administration (to avoid missed data resulting from the 
method Medicare uses when a patient receives both outpatient and inpatient claims on the 
same date) through 30 days after the last chemotherapy administration on record (Figure 3).
Cases remaining with “no hospitalizations” at this point formed that final group segment for 
comparative analysis (n = 333). The “all cancer-related hospitalizations” file was then 
restricted to include only admissions associated with dates within the hospitalization 
observation period for the eligible patient cases. The remaining observations formed the 
final hospitalization group for analysis (Figure 1). Table 2 describes the characteristics of 
nonhospitalized and hospitalized groups that composed this cohort.
Comorbidity Analysis
Both hospitalized and nonhospitalized cases underwent weighted comorbidity analysis, 
utilizing the NCI Combined Index (Klabunde, Legler, Warren, Baldwin, & Schrag, 2007) to 
provide a weighted comorbidity score for each patient case. The index extends the classic 
Charlson Comorbidity Index (CCI; Charlson, Pompei, Ales, & MacKenzie, 1987) to study 
designs that utilize administrative data generated from both the inpatient and outpatient 
areas. The presence (initially assigned a score of 1) or absence (assigned a score of 0) of 14 
noncancer conditions is detected from claims data. Each condition score is then multiplied 
by a coefficient estimate for two-year, noncancer mortality through use of a Cox 
proportional hazards model derived during method development (Klabunde, Potosky, 
Legler, & Warren, 2000). The weighted scores are then summed to provide a single value.
Analytic Methods
Data were available from 16 NCI-SEER registries. Based on geographical considerations, 
these data were grouped into four SEER registry regions. In order to properly account for 
geographical differences, and the resulting within region correlations that may occur with 
cases from the same region, population averaged statistical models were estimated using 
generalized estimating equations (GEE). Missing data were minimal, affecting less than 30 
cases where information on receipt of radiation was not documented. These cases were 
coded as if they did not receive or refused radiation in order to retain them in the overall 
analysis.
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GEE is a statistical modeling technique that builds on the classical generalized linear model 
to allow for within region correlated data (Liang & Zeger, 1986). For the first study aim, 
factors associated with the initial admission, the method was used with a binomial 
distribution and logit link to predict the probability of a “case/event” (i.e., hospitalization) as 
a linear function of predictors, in a similar manner to logistic regression. However, the 
variance of the binary response was adjusted for the likelihood that cases from the same 
region are more similar. Results are interpreted in terms of odds ratios, giving the likelihood 
of hospitalization versus nonhospitalization for each independent variable. For the second 
study aim, the GEE model with a Poisson distribution and log link was used to predict the 
number of hospitalizations, conditional on at least one hospitalization occurrence. Results 
are interpreted using an incidence rate (Rothman, 2002). Data step programming in SAS 
version 9.3 was used to perform data management, integration, and manipulation. Statistical 
modeling was completed with the PROC GENMOD SAS procedure.
After assessing the characteristics and frequency distributions of the independent variables, 
bivariate models were fit to assess the association between each independent variable with 
the dependent variable. A nominal level of significance of .05 was used. In the model-
building steps, a level of significance of .15 was used, and independent variables meeting 
this criterion in bivariate analyses were retained in further modeling stages. Advanced 
statistical modeling was then performed. After considering independent variables that were 
known to be associated with hospitalization, and including in each model by default 
regardless of statistical significance, we proceeded through an extensive model selection 
procedure. Two statistical criteria were considered in model building and selection. A two-
fold approach using statistical (p-values) and the quasi-likelihood under the independence 
model criterion (QIC) goodness of fit statistic (Pan, 2001) were used at each step of 
modeling to aid selection of the best final models (see Tables 3 and 4). We present results 
here of the unadjusted bivariate modeling and final multivariable modeling results. 
(Additional detailed results are available from the corresponding author upon request.)
The total amount of all charges for all services and the amount of payment made by 
Medicare to institutions associated with each identified unplanned hospitalization was 
computed through use of the MEDPAR file variables TOTCHRGS (total charges) and 
REIMBAMT (reimbursement amount), respectively. No adjustments, including cost-to-
charge ratio calculations, were made to these variables in this study, as the intent was to 
obtain a general estimate of the financial impact of potentially avoidable events.
Results
Cohort
The cohort consisted of 1,485 patients, 52.5% female, 11.4% of non-White race, with a 
mean age of 77.6 years. Of these, 77.5% (n = 1, 152) experienced at least one unplanned 
hospitalization. There were a total of 1, 522 hospitalizations, and the mean number per 
patient was 1.8 (SD = 1.3, range of 1 to17), with a median length of stay of five days. The 
total Medicare charges calculated for these admissions was $38,976,171, with the median 
charge per admission at $20,412. Median Medicare reimbursement per hospitalization 
equaled $6,734.
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Initial Unplanned Hospitalization
Factors examined for the relationship to initial unplanned hospitalization included age, 
comorbidity, sex, marital status, receipt of radiation therapy, race, education, income, 
urbanization, and SEER registry. After controlling for other variables in the adjusted model, 
the following factors were found to be significant: for each year of increasing age, the 
likelihood of hospitalization decreased by 6.1% (OR = 0.94, 95% CI: [0.92, 0.96], p < .
0001). Comorbidity was supported as a predictor, whereas compared with a weighted NCI 
Combined Index score of 3+ (indicating multiple comorbid conditions) patients with no 
comorbidities had a decreased likelihood of hospitalization of 78.1% (OR = 0.22, 95% CI: 
[0.10, 0.46], p < .0001). Those with a comorbidity score of 1 had a decreased likelihood of 
63.9% (OR = 0.36, 95% CI: [0.21, 0.62], p = .0002) and in those with a score of 2, the 
likelihood of hospitalization decreased by 44.2% (OR = 0.56, 95% CI: [0.28, 1.12], p = .10).
Female patients were more than twice as likely to be hospitalized as males (OR = 2.27, 95% 
CI: [1.84, 2.81], p < .0001). For each 10% increment decrease in census tract level rate of 
high school completion, the likelihood of hospitalization decreased by 6.02% (OR = 0.94, 
95% CI: [0.89, 0.99], p = .03), and for each $10,000 increment increase in census tract level 
median income, the likelihood of hospitalization decreased by 5.34% (OR = 0.95, 95% CI: 
[0.90, 0.99], p = .03). As compared to patients living in an area designated as completely 
rural (urban population less than 20,000), those living in counties with metro areas of one 
million or more (big metro) had a decreased likelihood of hospitalization of 31.4% (OR = 
0.69, 95% CI: [0.59, 0.80], p < .0001), and those in areas with an urban population of 
between 20,000 and one million (metro/urban) had a decreased likelihood of 41.6% (OR = 
0.58, 95% CI: [0.57, 0.60], p < .0001).
Number of Unplanned Hospitalizations
The same factors were examined related to the number of unplanned hospitalizations 
experienced. Controlling for other variables in the model, cases designated in the SEER 
record with a non-White race had 1.19 times the number of unplanned hospitalization as 
compared to Whites (95% CI: [1.03, 1.37], p < .02). Patients who received radiation therapy 
as part of their initial treatment plan had an increased number of hospitalizations, multiplied 
by 1.06 as compared to those who did not undergo that treatment (95% CI: [1.0, 1.12], p = .
03), and patients with a comorbidity score of 2 had 1.14 times the number of hospitalizations 
as compared to those with a score of 3 or more [95% CI: [1.10, 1.18], p < .0001). Degree of 
urbanization again influenced unplanned hospitalization. After controlling for other 
variables, as compared to those patients living in a completely rural area, those in a Big 
Metro area or Metro/Urban area had a decreased likelihood of unplanned hospitalization, 
multiplied by 0.80 (95% CI: [0.68, 0.93], p = .004) or 0.79 (95% CI: [0.71, 0.87], p < .
0001), respectively.
Discussion
This study examined predictors of unplanned hospitalization over the course of 
chemotherapy administration and management intended to be provided exclusively in the 
outpatient setting among patients with early-stage colorectal cancer. Consistent with the 
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literature described earlier, we observed that sex was a significant predictor, as females in 
the colorectal cohort experienced twice the likelihood of initial unplanned hospitalization 
than males. Sex was not a statistically significant predictor of the number of hospitalizations 
experienced.
Age was a significant predictor, but inverse to what was expected. Each year of additional 
age was associated with a 6% decrease in the likelihood of initial unplanned hospitalization. 
Though this may appear a counterintuitive result, a bias towards offering lower doses of 
anticancer treatments to patients based upon their chronologic age is evident in the literature 
(Hurria et al., 2008; Sargent et al., 2001; Sundararajan et al., 2002) and could contribute 
towards the appearance of fewer severe toxicities leading to hospitalization. Though the 
specific drugs administered could be precisely identified through billing data, the exact dose 
could not (as the unit of measurement is at the billed vial size), rather than indicative of true 
milligram per meter squared dosing.
A number of socioeconomic variables predicted unplanned hospitalizations in this study, 
including non-White race, living in a less densely populated area, a census tract with higher 
rates of high school graduation or a lower median income. Further study is needed to 
explore the true impact of these variables to individual patients—especially given the 
unexpected difference in directionality of the education and income findings—and a claims-
based data source may not be the most informative setting to explore these factors.
As expected, the influence of pre-existing comorbid conditions predicted unplanned 
hospitalizations. Compared to patients with an NCI Combined Index weighted score of 3 or 
greater, those with 0 (no comorbidities) or 1 were significantly less likely to experience an 
initial hospitalization. Patients with a score of 2 experienced an increased number of 
hospitalizations than those with scores of 0, 1, or 3 or more. This study utilized the total 
weighted index score for analysis, but this finding highlights the need for future inquiry 
regarding the impact of how specific comorbid conditions may impact chemotherapy 
toxicity and unplanned hospitalizations. It may be that certain conditions predispose patients 
more heavily than others, and the use of a single weighted score may not be as informative 
to predict risk.
Receipt of radiation therapy was a statistically significant predictor of the number of 
hospitalizations in the colorectal cohort, though it was not significant as a predictor of the 
initial admission. Radiation therapy is a localized intervention as compared with the 
systemic effects of chemotherapy, but may cause intense and lasting effects in the areas 
treated, such as nausea, vomiting and diarrhea, as well as dermatitis and bone marrow 
suppression (Baglan et al., 2002; Cai et al., 2013), possibly augmenting the systemic effects 
of chemotherapy.
Nursing implications
Though the results presented here require additional study before comprising an evidence-
based, clinically applicable risk factor profile, eventual development of such prospective 
tools for early identification of those patients most likely to experience unplanned 
hospitalizations will guide nurses to provide targeted, proactive interventions early in the 
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course of care where the effect will be most pronounced. Care protocols utilized by nurses in 
generalist and advanced practice roles may be targeted by risk level, including patient 
education with special instruction on important clinical signs and symptoms that should 
trigger urgent contact with the oncology service to obtain early outpatient management.
Future work
To build on these results, we are next working to apply the cohort development strategies to 
a regional electronic data warehouse (EDW) data source that will provide access to more 
extensive medical record-derived clinical data and a broader age range of patients. This type 
of inquiry will also facilitate clarification of specific pre-existing, noncancer comorbidities 
experienced, as well as race/ethnicity and the socioeconomic status variables that were 
significant in this study. Access to the EDW will provide more robust clinical data, such as 
chemotherapy dosing, patient functional status, symptom incidence, intensity, timing, and 
attempted outpatient management strategies implemented prior to an unplanned 
hospitalization, as well as more detail about the reason for the admission.
Additionally, subgroup analyses exploring the relationships between patients with specific 
organ system comorbidities and risk of unplanned hospitalizations for the most frequently 
observed toxicities are warranted. For example, a logical subanalysis would be to explore 
the toxicity patterns and risk of hospitalization in patients identified to have a diagnosis of 
diabetes prior to starting colorectal cancer treatments, as the high incidence of nausea and 
vomiting is likely to heavily impact this population. Identification of such clear-cut 
predictors will aid nurses to stratify education, supportive therapies, and patient monitoring 
to those patients at highest risk of avoidable complications.
Limitations
Though there are many advantages to utilization of a large dataset such as SEER-Medicare 
for nursing inquiry, it is important to note that a number of limitations exist. While claims 
data may provide clinical information (such as specific diagnostic and drug codes), reporting 
on key additional findings (such as symptom incidence and intensity), actual drug dosing, as 
well as functional status assessments, are not recorded in this way. Another challenge relates 
to data age. SEER-Medicare data typically lags two years behind availability, and is updated 
approximately every two years. For this study, which began in 2011, claims data were 
available through the end of 2009, and an update was not released until 2013, after which 
the majority of data analysis was completed.
It was hoped to include disease stage as a variable in the study models, but the proportion of 
cases where the diagnostic stage was coded as “unknown” (not missing) by the contributing 
cancer registry was significantly higher in the non-hospitalized group (X2 = 25.82, 1, p < .
0001), which was not compatible with GEE analysis. Most cancer registries reside within a 
hospital setting where medical record access is directly available, providing a possible 
explanation for the higher rate of SEER diagnostic classification among those patients in the 
hospitalized group.
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It is also important to note that the intent of this study was to identify predictive factors 
associated with the event of unplanned hospitalization among patients receiving 
chemotherapy—not to determine the specific causes of these admissions. The level of detail 
available in a claims-based dataset does not provide sufficient clinical information to 
accurately assess the etiology of unplanned hospitalizations.
Conclusion
This study represents a first step to identify patients prior to initiation of chemotherapy who 
are at high risk of severe treatment-related adverse events that may result in unplanned 
hospitalizations. Further work is needed to refine understanding of the impact of these 
factors and to add additional clinical variables, such as symptom experience, functional 
status, and chemotherapy dosing.
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FIGURE 1. 
Formation of the colorectal cohort. SEER-Medicare files initially contain the entire 
population of all patients with the requested tumor type diagnosed in contributing SEER 
sites across the nation. Eligibility and other study criteria quickly reduce the remaining 
population available for analysis.
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FIGURE 2. 
Logic model illustrating flow of cases into Hospitalized or Nonhospitalized groups within 
the colorectal cohort.
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FIGURE 3. 
Key dates defining the study observation periods.
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TABLE 1
SEER-Medicare File Types Utilized
File type Content Data Source Coding comment
PEDSF Demographics Age SEER Registry Continuous
Sex SEER Registry Categorical
Race SEER Registry Categorical
Marital status SEER Registry Categorical
Cancer diagnosis ICD-O-3a SEER Registry Categorical
Cancer stage SEER Registry Categorical
Local SEER Registry SEER Registry Categorical
Diagnosis date SEER Registry Transformed: SAS datesb
Initial treatment Radiation therapy SEER Registry Categorical
Census tract Education Census 2000 Non-HS graduates (%)
Income Census 2000 Mdn
Medicare coverage Parts A, B, or C (months) Medicare Categorical
Urbanization Population density 2004 ARF Categoricalc
NCH Outpatient claimsd Dates of caree Medicare Transformed: SAS datesb
Chemotherapy Medicare Categoricalf
ICD-9-CMg Medicare Continuous
OUTPT Outpatient claimsh Dates of caree Medicare Transformed: SAS datesb
Chemotherapy Medicare Categoricalf
ICD-9-CMg Medicare Continuous
MEDPAR Inpatient servicesi Dates of carej Medicare Transformed: SAS datesb
ICD-9-CMg Medicare Continuous
Note. ARF = Area Resource File; Mdn = median; MEDPAR = Medicare Provider Analysis and Review; NCH = National Carrier History ; OUTPT 
= Outpatient; PEDSF = Patient Entitlement and Diagnosis Summary File; SEER = Surveillance, Epidemiology, and End Results.
a
ICD-O-3 = International Classification of Diseases for Oncology, 3rd Edition.
bCalendar dates were transformed to SAS date values (number of days since January 1, 1960).
c
Big Metro = Counties of metro areas of 1 million population or more; Metro/Urban = Urban population of 20,000 through Counties in metro areas 
of up to 1 million population; Less Urban/Rural = Completely rural, or less than 2,500 urban population through Urban population up to 19, 999.
d
Provider and Medicare Part B claims from nonhospital, outpatient settings.
e
Date outpatient care service rendered.
f
Healthcare Common Procedure Coding System (HCPCS) J codes.
g
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
h
Provider and Medicare Part B claims from hospital-based outpatient settings.
i
Medicare Part A claims for inpatient services.
jAdmission and discharge dates.
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